vensobafusp alfa Drug Asset Due Diligence Report 2026

This vensobafusp alfa Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether vensobafusp alfa can convert its Fusion protein profile and C5 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	vensobafusp alfa (query alias: vensobafusp alfa)
Modality / target	Fusion protein; C5; C5 inhibitors
Highest global status	Phase 2
Originator	Not disclosed
Active developers	Kira Pharmaceuticals (Suzhou) Co., Ltd., Jasper Therapeutics, Inc., Kira Pharmaceuticals (Hong Kong) Ltd.

The MCP disease footprint includes C3 glomerulopathy, Glomerulonephritis, IGA, Hemoglobinuria, Paroxysmal. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT05517980	Phase 2	Not yet recruiting	52	Primary endpoint not disclosed in English source
NCT05504187	Phase 2	Not yet recruiting	24	Primary endpoint not disclosed in English source
NCT05490017	Phase 1	Completed	80	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

The role of red blood cell lifespan in evaluating the condition of patients with paroxysmal nocturnal hemoglobinuria treated with complement inhibitors

Not Applicable; n=22; evaluation: Positive. Reported fields: Coombs tests = positive in 3 patients treated with Crovalimab and all patients treated with Eculizumab ; Coombs tests = positive in 3 patients treated with Crovalimab and all patients treated with Eculizumab

KP104, a bifunctional C5 mAb–Factor h fusion protein, demonstrates sustained long-term efficacy and safety in complement inhibitor–naïve PNH patients: 2-year results from A phase 2 study with 8-week post-treatment safety follow-up.

Phase 2; n=18; evaluation: Positive. Reported fields: BTH events = 2.0 Event ; Hemoglobin level = 13.9 g/dL

KP104, a Bifunctional C5 Mab-Factor H Fusion Protein, Demonstrates Sustained Long-Term Efficacy and Safety in Complement Inhibitor-Naïve PNH Patients: Updated Results from a Phase 2 Study at 36/38 Weeks of Obd Treatment

Phase 2; n=18; evaluation: Positive. Reported fields: Hemoglobin level = +6.2 g/dL (SD, 2.0)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

vensobafusp alfa addresses C3 glomerulopathy, Glomerulonephritis, IGA, Hemoglobinuria, Paroxysmal. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Fusion protein—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 1 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2026-07-16	Jasper Therapeutics Announces Merger with Kira Pharmaceuticals	Preclinical	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Anti-c5 antibody fused to factor h for use in the treatment of complement-mediated diseases”. The milestone feed surfaced a patent-application signal described as “Biomarkers for monitoring effective treatment of neuromyelitis optica spectrum disorder (NMOSD) with complement component c5 inhibitors”. The milestone feed surfaced a patent-application signal described as “Anti-c5 antibody fused to factor h for use in the treatment of complement-mediated diseases”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Clinical differentiation versus current standards and pipeline competitors
Safety, dose optimization, and long-term tolerability
Patent scope, territorial rights, manufacturing, and commercial positioning

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO